Minimal Residual Disease Detected by the PCR in Chronic Myeloid Leukemia

Minimal residual disease quantitation in acute myeloid leukemia.

The prognosis for patients with acute myeloid leukemia (AML) is heterogeneous. A minority of patients have clinical and biologic features associated with a very high risk of relapse. For the remaining patients, no clear prognostic factors can be identified at diagnosis. The degree of treatment response is likely to be an informative predictor of outcome for these patients. Modern assays to dete...

Detection of minimal residual disease in acute myeloid leukemia.

Acute myeloid leukemia (AML) is a curable malignancy, but its cure rate remains disappointingly low. Accurate quantitation of residual AML cells would allow individualization of therapy and thereby increase the likelihood of cure for each patient. Techniques that are being studied for residual disease detection include molecular assays for abnormalities that are present in subsets of AML patien...

The detection and significance of minimal residual disease in chronic myeloid leukemia.

The focus of the study of minimal residual disease (MRD) is to redefine the concept of remission by using more sensitive molecular techniques to detect level of disease burden below that of conventional pathology. The detection of the chimeric bcr-abl mRNA transcript in chronic myeloid leukemia (CML) is a paradigm of the use of molecular biology for clinical applications. The qualitative (yes v...

The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia.

BACKGROUND AND OBJECTIVES Accurate quantification of BCR-ABL mRNA is of critical importance for managing patients with chronic myeloid leukemia (CML) who are receiving imatinib therapy. RNA degradation thus constitutes a potential problem for laboratories quantifying minimal residual disease (MRD). Patients' samples that take a long time to be transported from the hospital to the analyzing labo...

Evaluation of Relationship between Minimal Residual Disease (MRD) and Relapse in Childhood Acute Lymphoblastic Leukemia (ALL) Using Quantitative Fluorescent PCR